These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 38256429)

  • 21. Comparative Accuracy of Clinical Fibrosis Markers, Hepascore and Fibroscan® to Detect Advanced Fibrosis in Patients with Nonalcoholic Fatty Liver Disease.
    Bertot LC; Jeffrey GP; de Boer B; Wang Z; Huang Y; Garas G; MacQuillan G; Wallace M; Smith BW; Adams LA
    Dig Dis Sci; 2023 Jun; 68(6):2757-2767. PubMed ID: 36947289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical profile of non-alcoholic fatty liver disease in nonobese patients.
    Lum JHM; Cheah MCC; Leow WQ; Wan WK; Lim TKH; Chow WC; Chang JPE; Goh GBB
    J Gastroenterol Hepatol; 2021 Jan; 36(1):257-261. PubMed ID: 32557741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: A multicenter study.
    Han MAT; Vipani A; Noureddin N; Ramirez K; Gornbein J; Saouaf R; Baniesh N; Cummings-John O; Okubote T; Setiawan VW; Rotman Y; Loomba R; Alkhouri N; Noureddin M
    Liver Int; 2020 Sep; 40(9):2242-2251. PubMed ID: 32652744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease.
    Younossi ZM; Felix S; Jeffers T; Younossi E; Nader F; Pham H; Afendy A; Cable R; Racila A; Younoszai Z; Lam BP; Golabi P; Henry L; Stepanova M
    JAMA Netw Open; 2021 Sep; 4(9):e2123923. PubMed ID: 34529067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of the combined FibroMeter vibration-controlled transient elastography algorithm in Chinese patients with non-alcoholic fatty liver disease.
    Loong TC; Wei JL; Leung JC; Wong GL; Shu SS; Chim AM; Chan AW; Choi PC; Tse YK; Chan HL; Wong VW
    J Gastroenterol Hepatol; 2017 Jul; 32(7):1363-1369. PubMed ID: 27936280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Six Noninvasive Methods for the Detection of Fibrosis in Chinese Patients with Obesity and Nonalcoholic Fatty Liver Disease.
    Chen G; Yang JC; Zhang GX; Cheng Z; Du X
    Obes Surg; 2022 Nov; 32(11):3619-3626. PubMed ID: 36070119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transient Elastography and Serum-Based Tests for Diagnosis of Fatty Liver and Advanced Fibrosis in a Community Cohort: A Cross-Sectional Analysis.
    Le MH; Henry L; Cheung R; Nguyen MH
    Dig Dis; 2023; 41(5):767-779. PubMed ID: 35973400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-invasive tests accurately stratify patients with NAFLD based on their risk of liver-related events.
    Boursier J; Hagström H; Ekstedt M; Moreau C; Bonacci M; Cure S; Ampuero J; Nasr P; Tallab L; Canivet CM; Kechagias S; Sánchez Y; Dincuff E; Lucena A; Roux M; Riou J; Trylesinski A; Romero-Gomez M
    J Hepatol; 2022 May; 76(5):1013-1020. PubMed ID: 35063601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis.
    Singh S; Venkatesh SK; Loomba R; Wang Z; Sirlin C; Chen J; Yin M; Miller FH; Low RN; Hassanein T; Godfrey EM; Asbach P; Murad MH; Lomas DJ; Talwalkar JA; Ehman RL
    Eur Radiol; 2016 May; 26(5):1431-40. PubMed ID: 26314479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.
    Tan EX; Lee JW; Jumat NH; Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Lesmana LA; Zheng KI; Zheng MH; Koh CJ; Ho KY; Goh KL; Wong VW; Dan YY
    Metabolism; 2022 Jan; 126():154911. PubMed ID: 34648769
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New FIB-4 and NFS cutoffs to guide sequential non-invasive assessment of liver fibrosis by magnetic resonance elastography in NAFLD.
    Torres L; Schuch A; Longo L; Valentini BB; Galvão GS; Luchese E; Pinzon C; Bartels R; Álvares-da-Silva MR
    Ann Hepatol; 2023; 28(1):100774. PubMed ID: 36280013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Noninvasive diagnosis of fibrosis in non-alcoholic fatty liver disease: diagnostic accuracy of different scores.
    Durazzo M; Marzari L; Bonetto S; Ferro A; Ghigo MC; Belci P; Collo A; Fagoonee S
    Minerva Gastroenterol Dietol; 2020 Dec; 66(4):301-306. PubMed ID: 32700500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative diagnostic performance of ultrasound shear wave elastography and magnetic resonance elastography for classifying fibrosis stage in adults with biopsy-proven nonalcoholic fatty liver disease.
    Zhang YN; Fowler KJ; Boehringer AS; Montes V; Schlein AN; Covarrubias Y; Wolfson T; Hong CW; Valasek MA; Andre MP; Loomba R; Sirlin CB
    Eur Radiol; 2022 Apr; 32(4):2457-2469. PubMed ID: 34854929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. US Time-Harmonic Elastography: Detection of Liver Fibrosis in Adolescents with Extreme Obesity with Nonalcoholic Fatty Liver Disease.
    Hudert CA; Tzschätzsch H; Guo J; Rudolph B; Bläker H; Loddenkemper C; Luck W; Müller HP; Baumgart DC; Hamm B; Braun J; Holzhütter HG; Wiegand S; Sack I
    Radiology; 2018 Jul; 288(1):99-106. PubMed ID: 29762096
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repeated measurements of non-invasive fibrosis tests to monitor the progression of non-alcoholic fatty liver disease: A long-term follow-up study.
    Balkhed W; Åberg FO; Nasr P; Ekstedt M; Kechagias S
    Liver Int; 2022 Jul; 42(7):1545-1556. PubMed ID: 35319156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease.
    Mahadeva S; Mahfudz AS; Vijayanathan A; Goh KL; Kulenthran A; Cheah PL
    J Dig Dis; 2013 Nov; 14(11):604-10. PubMed ID: 23859493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
    Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
    Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.